Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Optimized SARS-CoV-2 Molecular Quality Controls Released by ZeptoMetrix®

ZeptoMetrix® announces the immediate availability of it's ready-to-use, NATtrol™ inactivated, whole intact SARS-CoV-2 molecular quality control - NATSARS(COV2)-ERC - for laboratory QC and test validation.


News provided by

ZeptoMetrix

May 05, 2020, 03:00 ET

Share this article

Share toX

Share this article

Share toX

NATSARS(COV2)-ERC NATtrol SARS-CoV-2 Positive Quality Control
NATSARS(COV2)-ERC NATtrol SARS-CoV-2 Positive Quality Control

BUFFALO, N.Y., May 5, 2020 /PRNewswire-PRWeb/ -- Continuing in its efforts to rapidly respond to today's COVID-19 pandemic, ZeptoMetrix Corporation (ZMC) announced today the development and release of a ready-to-use SARS-CoV-2 molecular quality control formulated with purified intact viral particles that have been chemically modified to render them non-infectious and refrigerator stable:

  •     NATtrol SARS-CoV-2 Positive Control
  •     Product Number: NATSARS(COV2)-ERC

“Due to the unprecedented COVID-19 pandemic, we were tasked to develop and deploy reliable, user-friendly commercial solutions for ready-to-use, non-infectious SARS-CoV-2 full process molecular quality controls under accelerated timelines."

Post this

Complementing the release of the positive control is a negative control formulated with human A549 cells:

  •     NATtrol SARS-CoV-2 Negative Control
  •     Product Number: NATSARS(COV2)-NEG

"Due to the unprecedented COVID-19 pandemic, we were tasked to develop and deploy reliable, user-friendly commercial solutions for ready-to-use, non-infectious SARS-CoV-2 full process molecular quality controls under accelerated timelines. Today, I am extremely proud to announce that ZeptoMetrix has launched such controls - containing purified intact viral particles of actual SARS-CoV-2 that provide laboratories, hospitals and research facilities with essential external run controls to help ensure the reliability of COVID-19 testing", explains Shawn R. Smith, President & CEO of ZeptoMetrix.

"In conjunction with our existing and ever expanding product portfolio, we recognize the responsibility embodied by our company's ability to meet today's challenges and to positively impact public health efforts by leveraging the many capabilities we possess. From initial sourcing of the virus to carefully controlled processing in containment labs and through the array of technical, operational and logistical resources deployed against this endeavor, our company rose to the challenge by displaying the commitment and perseverance required to succeed, especially in these challenging times."

Today more than ever, it is critical to global healthcare that we have a more complete understanding of Infectious Diseases and the diagnostic technologies employed in their testing. ZeptoMetrix has enhanced its coronavirus product line and has made it a priority to ensure product availability to diagnostic companies developing new and improved tests as well as those laboratories in hospitals and clinics seeking to ensure the reliability of the tests they perform.

ZEPTOMETRIX CORONAVIRUS PRODUCTS:

SARS-CoV-2
NATtrol SARS-CoV-2 Positive Control – NATSARS(COV2)-ERC
NATtrol SARS-CoV-2 Negative Control - NATSARS(COV2)-NEG
NATtrol SARS-CoV-2 Stock - NATSARS(COV2)-ST
SARS-CoV-2 Isolate: USA-WA1/2020 Heat Inactivated Culture Fluid - 0810587CFHI-0.5ML
SARS-CoV-2 Isolate: USA-WA1/2020 Heat Inactivated Culture Fluid - 0810587CFHI

SARS-CoV-2 Recombinant
NATtrol SARS-CoV-2 (recombinant) Stock - 0831042
NATtrol SARS-CoV-2 (E/ORF1ab recombinant) Stock – 0831043

SARS 2003-00592
NATtrol Coronavirus SARS Stock - NATSARS-ST

Coronavirus 229E
NATtrol Coronavirus 229E Stock - NATCOV(229E)-ST
Coronavirus Strain: 229E Culture Fluid - 0810229CF
Coronavirus Strain: 229E Heat Inactivated Culture Fluid - 0810229CFHI
Coronavirus Strain: 229E Lysate - 0810229

Coronavirus NL63
NATtrol Coronavirus NL63 Stock - NATCOV(NL63)-ST
Coronavirus Strain: NL63 Culture Fluid - 0810228CF
Coronavirus Strain: NL63 Heat Inactivated Culture Fluid - 0810228CFHI
Coronavirus Strain: NL63 Lysate - 0810228

Coronavirus OC43
NATtrol Coronavirus OC43 Stock - NATCOV(OC43)-ST
Coronavirus Strain: OC43 Culture Fluid - 0810024CF
Coronavirus Strain: OC43 Heat Inactivated Culture Fluid - 0810024CFHI
Coronavirus Strain: OC43 Lysate - 0810024

MERS-CoV Florida/USA-2_Saudi Arabia_2014
NATtrol MERS-CoV Stock - NATMERS-ST
MERS-CoV Strain: Florida/USA-2_Saudi Arabia_2014 Culture Fluid - 0810575CF
MERS-CoV Strain: Florida/USA-2_Saudi Arabia_2014 Heat Inactivated Culture Fluid - 0810575CFHI

About ZeptoMetrix®
ZeptoMetrix Corporation (ZMC) is an established industry leader in the design, development, and delivery of innovative, quality solutions to the Infectious Disease Diagnostics Market. Our expertise and abilities in Molecular Diagnostics, including External Quality Controls, Verification Panels, Proficiency Panels, Customized and OEM Products/Services have set the industry standard for performance and reliability and made ZeptoMetrix the preferred choice for independent 3rd party QC materials.

Founded in 1999, ZeptoMetrix is headquartered in Buffalo, NY with additional facilities in Franklin, Massachusetts.

About NATtrol™
Globally, millions of people are tested for infectious diseases each year. The implications of reporting either a false positive or a false negative can be devastating to the patient. Accurate and sensitive diagnostics are necessary to confirm that laboratories are providing patients with proper testing results. Utilizing ZeptoMetrix NATtrol QC materials on a consistent basis helps to monitor testing performance and enhance confidence in testing results.

ZeptoMetrix NATtrol Molecular Diagnostics products are an essential component of today's ever-evolving testing market and are designed to provide safe, accurate and cost-effective support for activities relating to the analysis and identification of possible disease-causing microorganisms. The patented ZeptoMetrix NATtrol process renders highly-purified microorganisms non-infectious while allowing internal nucleic acids to remain intact, thereby serving as an ideal reference material for molecular diagnostic testing applications. Representing a total process control, from DNA extraction through amplification and eventual detection, NATtrol products are ready-to-use, refrigerator stable, and safe for operators to handle.

The routine and repetitive use of NATtrol™ External Run Controls and Verification Panels help enable laboratories to monitor performance and identify trends in daily test variations, test kit lot changes, and among individual operators.

For Sales and/or information regarding ZeptoMetrix, NATtrol Molecular Quality Controls & Panels, and Development/Custom Services, please contact ZeptoMetrix Customer Service.

Contact:
ZeptoMetrix Corporation, Customer Service
878 Main Street
Buffalo, NY 14202
716-882-0920
[email protected]

Media:
Michael Hershfield, Vice President, Sales & Marketing
508-553-5852
[email protected]

SOURCE ZeptoMetrix

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.